Georgia Cancer Center

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Endometrial cancer2 trials
• Ovarian cancer2 trials
• Acute myeloid leukaemia1 trial
• Chronic lymphocytic leukaemia1 trial
• Follicular lymphoma1 trial
• Hodgkin lymphoma1 trial
• Lung cancer1 trial
• Mantle cell lymphoma1 trial
• Myeloproliferative neoplasms1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 22 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 2/31 trial
• Phase 31 trial

Status

• Completed3 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial

Lead sponsor

• Incyte Corporation3 trials
• Actuate Therapeutics Inc.1 trial
• Beat AML, LLC1 trial
• Bio-Path Holdings, Inc.1 trial
• Eisai Inc.1 trial

Running trials

• Recruiting

  Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

  NCT05919511· Incyte Corporation· Source

• Active, not recruiting

  A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

  NCT04072458· Phase 1· Bio-Path Holdings, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  NCT04300556· Phase 1/2· Eisai Inc.· Source

• Recruiting

  Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

  NCT03013998· Phase 2/3· Beat AML, LLC· Source

  Contact: Yenny Moreno Vanegas, MD (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Completed

  Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

  NCT04463771· Phase 2· Incyte Corporation· Source

• Completed

  Actuate 1901: 9-ING-41 in Myelofibrosis

  NCT04218071· Phase 2· Actuate Therapeutics Inc.· Source